We have chosen to demonstrate the survival benefit to melanoma cells of their RAD51 response to cisplatin in a combination of short term growth, cell cycle analysis and apoptosis assays rather than conventional colony formation assays because we consider it more closely represents the in vivo situation. Here, RAD51 is linked to melanoma.